JHJiaofeng Huang

Jiaofeng Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiaofeng Huang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Su Lin

    Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China

    11 shared publications
  • Yueyong Zhu

    Liver Disease Diagnosis and Treatment Center, The First Affiliated Hospital of Fujian Medical University

    6 shared publications
  • Mingfang Wang

    Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

    5 shared publications
  • Rahul Kumar

    Department of Gastroenterology, Changi General Hospital, Singapore, Singapore

    5 shared publications
  • Mingfang Wang

    Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China

    4 shared publications
  • Yinlian Wu

    Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China

    4 shared publications

Latest Publications

  • Open Access

    Helicobacter pylori is associated with a higher risk of MAFLD prevalence and all-cause mortality: results from the NHANES III follow-up study

    by Qichao Fan, Yachun Chen, Junjin Liu, Liang Gao, Jiaofeng Huang

    Aim: This study examined the relationship between Helicobacter pylori (H. pylori) and metabolic dysfunction-associated fatty liver disease (MAFLD) and concurrently evaluated their association with all-cause mortality risk. Methods: Data were extracted from the Third National Health and Nutrition Examination Survey, which included 5,073 participants with available H. pylori IgG serology [enzyme-linked immunosorbent assay (ELISA)] results and mortality data. Logistic regression was used to assess the relationship between H. pylori seropositivity and MAFLD risk, while Cox proportional hazards regression was used to evaluate all-cause mortality risk, with adjustment for confounders. Results: Among 5,073 participants, 2,394 (47.2%) tested positive for H. pylori and 1,610 (31.7%) had MAFLD; during a median follow-up of 28.8 years, 1,891 deaths occurred (overall mortality rate 37.3%). H. pylori-seropositive individuals exhibited significantly higher mortality rates than seronegative individuals (43.5% vs. 31.7%, P < 0.001). Multivariate logistic regression confirmed H. pylori seropositivity as an independent risk factor for MAFLD [adjusted odds ratio (OR) = 1.282, 95% confidence interval (CI): 1.126-1.459, P < 0.001]. Multivariate Cox regression revealed that H. pylori seropositivity independently increased mortality risk (adjusted HR = 1.253, 95%CI: 1.139-1.379, P < 0.001), which was consistent across the MAFLD and non-MAFLD subgroups. Kaplan-Meier analysis corroborated significant survival divergence (log-rank, P < 0.001). Conclusion: This study indicates that H. pylori seropositivity is independently associated with a higher prevalence of MAFLD and greater mortality risk in community-dwelling individuals.

  • Open Access

    The impact of the COVID-19 pandemic on the global burden of type 2 diabetes: a study based on GBD 2021 data

    by Xiaoqin Chen, Hui Lin, Yinlian Wu, Mingfang Wang, Su Lin, Jiaofeng Huang

    Background: This study aimed to comprehensively assess the impact of the coronavirus disease 2019 (COVID-19) pandemic on the global burden of type 2 diabetes mellitus (T2DM) using data from the Global Burden of Diseases (GBD) 2021.Methods: Age-standardized T2DM prevalence, incidence, mortality, and disability-adjusted life years (DALYs) were analyzed from Global Burden of Diseases (GBD) 2021. Pre-pandemic (2010–2019) and post-pandemic (2020–2021) periods were defined to capture pandemic onset, with 2020–2021 as the earliest available global post-pandemic data. Expected annual percentage changes (EAPC) were derived to assess the magnitude and direction of trends over the study period, adjusting for age, sex, and sociodemographic index. Post-pandemic projections to 2030 employed a Bayesian model with pre-/post-pandemic slope comparisons.Results: Global T2DM prevalence (ages ≥20) rose from 6,887.07 per 100,000 in 2010 to 9,545.42 per 100,000 in 2021. Post-pandemic acceleration was observed: EAPC increased from 2.90% (95% CI: 2.86–2.94) pre-pandemic to 3.52% (95% CI: 3.14–3.90) post-pandemic. Mortality and DALYs showed similar accelerations. Despite continued increases in incidence, mortality, and DALYs, the EAPC decreased in the post-pandemic period. Projections using pre-pandemic data (up to 2019) estimated type 2 diabetes prevalence at 10368.23 per 100,000 population by 2030. However, incorporating post-pandemic data (up to 2021) increased the projected 2030 prevalence to 10694.79 per 100,000, indicating a rise of 326.56 per 100,000 attributed to the pandemic’s impact. The prevalence, incidence, deaths, and DALYs of CKD due to T2DM all showed an upward trend from 2010 to 2021.Conclusions: A rapid increase in the burden of T2DM is found post-COVID-19 pandemic. Enhanced public health interventions are required for the prevention, screening, and management of diabetes.


  • Top Cited Papers
    Open Access

    Evaluating the global, regional, and national impact of syphilis: results from the global burden of disease study 2019

    by Tao Chen, Bo Wan, Mingfang Wang, Su Lin, Yinlian Wu, Jiaofeng Huang

    Syphilis is a global public health concern. This study aimed to assess the global and regional burden of syphilis from 1990 to 2019. Disease burden was evaluated using disability-adjusted life-years (DALYs) and prevalence. Data were extracted from the 2019 global burden of disease Study, an open database available for download. Age-standardized rates (ASR) and estimated annual percentage changes (EAPC) were calculated to evaluate the syphilis burden over time. In 2019, the total number of prevalent cases of syphilis was 49.71 million worldwide. The ASR of prevalence was stable from 1990 to 2019 with an EAPC of 0.00 (95% CI − 0.10–0.11). The number of DALYs caused by syphilis was 7.36 million in 2019, reflecting a reduction of 16.38% compared with that in 1990 (8.80 million). The ASR of DALYs exhibited a decreasing trend from 1990 to 2019 (EAPC = − 1.01; 95% CI − 1.19 to − 0.84), with the highest rates observed in the younger age group (< 14 years old). In 2019, the highest ASR of DALYs was found in low sociodemographic index (SDI) regions (239.21/100,000), and the lowest in high SDI regions (3.14/100,000). Generally, the ASR of DALYs decreased as the SDI increased. The top three countries with the highest ASR of DALYs for syphilis were the Solomon Islands, Equatorial Guinea, and Liberia. While the global prevalence of syphilis remained persistently high from 1990 to 2019, there has been a recent decrease in the ASR of DALYs. Increased attention should be dedicated to younger populations and regions characterized by low SDIs.


  • The association between serum 25‐hydroxyvitamin D and the prevalence of herpes simplex virus

    by Jiaofeng Huang, Yinlian Wu, Mingfang Wang, Su Lin

    Previous studies have reported a potential anti‐infection effect for vitamin D. However, the relationship between vitamin D status and herpes simplex virus (HSV) infection has not yet been evaluated. Therefore, this study aimed to determine the association between serum 25‐hydroxyvitamin D [25(OH)D] and infection with HSV types 1 and 2 (HSV‐1 and HSV‐2). Data were collected from the National Health and Nutrition Examination Survey from 2007 to 2016. The association between 25(OH)D and HSV prevalence was evaluated using propensity score matching (PSM) and univariate and multivariate logistic regression analyses. Overall, 14 174 participants were included in the final analysis. Before PSM, 8639 (60.9%) had positive HSV‐1 and 2636 (18.6%) had HSV‐2. The HSV‐1 and HSV‐2 positive groups had more females and older individuals ( p < 0.05). The HSV‐2 patients had lower 25(OH)D levels than those with HSV‐1. Age and gender did not differ in the groups after PSM ( p > 0.05). The 25(OH)D level was significantly lower in the HSV‐1 and HSV‐2 groups than in the non‐HSV infection groups. Multivariate logistic regression showed that serum 25(OH)D level was negatively associated with HSV‐1 and HSV‐2 infection (odds ratio [OR] = 0.730 and 0.691, p < 0.001, respectively). Vitamin D deficiency was an independent risk factor for both HSV‐1 and HSV‐2 (adjusted OR = 2.205 and 2.704, p < 0.001, respectively). Lower serum 25(OH)D levels correlated significantly with increased HSV‐1 and HSV‐2 infection risk.


  • Open Access

    The association between Toxoplasma infection and mortality: the NHANES epidemiologic follow-up study

    by Jiaofeng Huang, Jiaolong Zheng, Bang Liu, Lingling Lu, Haicong Wu, Su Lin, Dongliang Li

    Background: Toxoplasma gondii has been reported to be associated with higher mortality in patients with schizophrenia. This study aimed to explore the relationship between T. gondii infection and 25-year mortality based on data from the Third National Health and Nutrition Examination Survey (NHANES III) database. Methods: Cases with serum T. gondii antibody test results were included in this study and the corresponding mortality dataset was obtained from the US National Center for Health Statistics (NCHS). Propensity score matching (PSM) was used to match age and sex between groups. The Cox proportional hazards model was used to evaluate the effect of T. gondii infection on mortality. Results: A total of 14,181 cases were included in the analysis, of which 3831 (27.0%) were seropositive for T. gondii antibody. The median follow-up time of the whole cohort was 22.5 (interquartile range 16.3, 24.5) years. A total of 5082 deaths were observed in this cohort, a mortality rate of 35.8%. All-cause mortality was significantly higher in the seropositive group than in the seronegative group (50.0% vs 30.6%, P < 0.001). Kaplan–Meier analysis showed a significant difference in the survival time between two groups before and after PSM. Multivariate analysis showed that T. gondii infection was independently associated with higher all-cause mortality after adjusting for potential confounders. Conclusions: Toxoplasma gondii infection is associated with higher mortality in general population. Graphical


  • Spatial−temporal analysis of HIV/AIDS and syphilis in mainland China from 2007 to 2017

    by Jiaofeng Huang, Haicong Wu, Su Lin, Lingling Lu, Jiaolong Zheng, Bang Liu, Rahul Kumar, Dongliang Li

    Human immune deficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and syphilis are the most common sexually transmitted diseases (STDs) worldwide, as well as in China. The objective of this study is to describe the trend of spatial and temporal variation of HIV/AIDS and syphilis in mainland China from 2007 to 2017. Stratified analysis was conducted according to age and the GDP per capita. Estimated Annual Percentage Change (EAPC) was calculated and spatial autocorrelation analysis was used to evaluate the epidemiology and identify clusters. The morbidity of new HIV infection increased from 2.5034/100 000 in 2007 to 6.9247/100 000 in 2017, with an EAPC of 9.84 (95% confidence interval [CI]: 9.07–10.60). From 2007 to 2017, the morbidity of syphilis presented a significant upward trend from 15.8834/100 000 to 34.4867/100 000 (EAPC = 6.48, 95% CI: 4.23–8.73). The number of new HIV infections (205 084) and syphilis (921 279) were highest in the 20–30 years old group, where the incidence decreased with age over 20 years. In general, HIV and syphilis infection had the same incidence trend according to age and time stratification. The morbidity of new HIV infection was mainly reported from Xinjiang and southwestern China. As for syphilis, the highest was found in Zhejiang in Xinjiang and southeast coastal areas. Both HIV and syphilis infection showed a nonrandom positive correlation by Moran's I value. The High‐High cluster areas of HIV infection were concentrated in southwestern and eastern China due to syphilis. A highly significant positive correlation was found between gross domestic product per capita and syphilis infection (p < 0.05) but was not associated with HIV infection. The incidence of AIDS/HIV and syphilis is increasing year by year, and a higher prevalence is found in younger individuals. More attention should be paid to HIV infection in the southwest, syphilis in southeast coastal areas, and both the two diseases in Xinjiang.


  • Open Access

    Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease

    by Xiaoning Chen, George Boon-Bee Goh, Jiaofeng Huang, Yinlian Wu, Mingfang Wang, Rahul Kumar, Su Lin, Yueyong Zhu

    Metabolic-associated fatty liver disease (MAFLD) is a newly proposed terminology from 2020; yet, the applicability of conventional noninvasive fibrosis models is still unknown for it. We aimed to evaluate the performance of conventional noninvasive fibrosis scores in MAFLD.


  • The global disease burden of varicella‐zoster virus infection from 1990 to 2019

    by Jiaofeng Huang, Yinlian Wu, Mingfang Wang, Jiaji Jiang, Yueyong Zhu, Rahul Kumar, Su Lin

    Data on the global epidemiology of varicella‐zoster virus infection (VZVI) is limited. This study aimed to investigate the burden of VZVI based on the global burden of disease study 2019 data. The age‐standardized rates, including the incidence, death, disability‐adjusted life years (DALYs), and the estimated annual percentage changes (EAPC) of VZVI were calculated to evaluate the disease burden of VZVI. The global numbers of incident and death cases due to VZVI were 83 963 744 and 14 553, respectively. The age‐standardized incidence rate of VZVI increased slightly all over the world, while the age‐standardized death and DALYs rate decreased from 1990 to 2019 (EAPC = −2.31 and −1.61, respectively). The younger age (<5 years old) and older groups had the highest VZVI burden. The high sociodemographic index (SDI) region had the highest age‐standardized incidence rates in 2019 (1236.28/100 000, 95% uncertainty interval [UI]: 1156.66–1335.50) and the low SDI region had the lowest incidence (1111.24/100 000, 95% UI: 1040.46–1209.55). The age‐standardized death and DALYs rate of VZVI decreased with the increase of SDI. Amongst the 21 geographical regions, the high‐income Asia‐Pacific (1269.08/100 000) region had the highest age‐standardized incidence rate in 2019, while Sub‐Saharan Africa had the highest age‐standardized death and DALYs rate. The global incidence of VZVI has continued to increase in the past 3 decades, while the age‐standardized death and DALYs rates have decreased. More attention should be paid to the younger and older population, as well as low SDI regions.


  • Open Access

    MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis

    by Jiaofeng Huang, Wenjuan Xue, Mingfang Wang, Yinlian Wu, Medha Singh, Yueyong Zhu, Rahul Kumar, Su Lin

    Introduction: Metabolic associated fatty liver disease (MAFLD) is a novel concept for fatty liver disease. Different from non-alcoholic fatty liver disease (NAFLD), the diagnosis of MAFLD requires the presence of metabolic risks. This study aimed to characterize patients with liver steatosis but without metabolic risks (non-MR-steatosis) which may not be diagnosed by MAFLD criteria. Methods: Consecutive patients who underwent biopsy were included in this study. The clinic-pathological characteristics of non-MR-steatosis, NAFLD and MAFLD were compared. Results: A total of 1217 cases were included. There were 426 (35.00%) cases with MAFLD, 585 (48.07%) with NAFLD and 168 (13.80%) with non-MR-steatosis. The majority of the cases were infected with HBV (93.26%). The age and metabolic profiles were highest in MAFLD and lowest in non-MR-steatosis. The body mass index (BMI) level was also lowest in non-MR-steatosis (20.78 ± 1.54 kg/m2). The ALT and AST levels of the non-MR-steatosis group were not statistically different from those of MAFLD or NAFLD groups (p > 0.05). Histologically, there was no significant difference in the degrees of inflammation and fibrosis among the three groups. The severity of steatosis in non-MR-steatosis group was lower than MAFLD or NAFLD groups (p < 0.05). These results were consistent in both HBV and non-HBV subgroups. Conclusion: MAFLD criteria may overlook some steatotic patients without metabolic risks, who may also have steatohepatitis and significant fibrosis.


  • Top Cited Papers

    The impact of COPD and smoking history on the severity of COVID‐19: A systemic review and meta‐analysis

    by Qianwen Zhao, Meng Meng, Rahul Kumar, Yinlian Wu, Jiaofeng Huang, Ningfang Lian, Yunlei Deng, Su Lin

    Comorbidities are associated with the severity of coronavirus disease 2019 (COVID‐19). This meta‐analysis aimed to explore the risk of severe COVID‐19 in patients with pre‐existing chronic obstructive pulmonary disease (COPD) and ongoing smoking history. A comprehensive systematic literature search was carried out to find studies published from December 2019 to 22 March 2020 from five databases. The languages of literature included English and Chinese. The point prevalence of severe COVID‐19 in patients with pre‐existing COPD and those with ongoing smoking was evaluated with this meta‐analysis. Overall 11 case series, published either in Chinese or English language with a total of 2002 cases, were included in this study. The pooled OR of COPD and the development of severe COVID‐19 was 4.38 (fixed‐effects model; 95% CI: 2.34‐8.20), while the OR of ongoing smoking was 1.98 (fixed‐effects model; 95% CI: 1.29‐3.05). There was no publication bias as examined by the funnel plot and Egger's test (P = not significant). The heterogeneity of included studies was moderate for both COPD and ongoing smoking history on the severity of COVID‐19. COPD and ongoing smoking history attribute to the worse progression and outcome of COVID‐19.